National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dolutegravir (Tivicay®) is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age.

 Rapid Review

Commenced Completed Outcome
10/02/2014 13/03/2014 Full Pharmacoeconomic Evaluation not recommended